CommercialCoverageMedium impact
08.01.95c, Risankizumab-rzaa (Skyrizi®) for Intravenous Use
Independence Blue Cross·Gastroenterology, Dermatology, Rheumatology·Pharmacy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.95c for Risankizumab-rzaa (Skyrizi®) intravenous use has been reissued with an effective date of November 26, 2025. This is a commercial policy update that may affect coverage, billing, or prior authorization requirements for this specialty medication used to treat conditions like psoriasis and Crohn's disease.
Action Required
By November 26, 2025: Billing team should review the updated policy details for Risankizumab-rzaa (Skyrizi®) IV administration to understand any changes to coverage criteria, prior authorization requirements, or billing procedures. Contact the payer or access the full policy document to determine specific billing impacts and update workflows accordingly.